Integrative Cancer Therapies

Bestqool Introduces Revolutionary Red Light Therapy for Home-Based Yogis: A New Horizon in Wellness and Yoga Practice

Retrieved on: 
Friday, March 22, 2024
Well, AIMS, Glass, Yoga, COVID-19, Education, Link, Tissue, Research, Muscle fatigue, Joint, Student, Aesthetic Surgery Journal, Woman, Integrative Cancer Therapies, Patient satisfaction, Safety, Human factors and ergonomics, Red light, Martin, Biophysics, Health care

Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.

Key Points: 
  • Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.
  • It is recommended that all home-based yogis and yoga practitioners incorporate the use of Red Light Therapy at three stages of their lives, that is before, during, and after their yoga sessions.
  • Furthermore, Red Light therapy would work as a much-needed companion for your yoga sessions.
  • Bestqool 's hand-held Red Light Therapy devices are designed with the user in mind, offering ease of use, safety, and efficiency.

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

Retrieved on: 
Wednesday, May 18, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Linda, Physician, Breast, B cell, Company, Good manufacturing practice, Food, US Foods, U.S. Securities and Exchange Commission, FIH, GMP, Enzyme, Pancreas, Trypsinogen, Patient, Prostate, Science, MHRA, Liver, PPCB, Kidney, Research, FDA, Koch Institute for Integrative Cancer Research, Brain, Recurrence, Accounting, Metastasis, Medicines and Healthcare products Regulatory Agency, Chymotrypsinogen, Good, Human, Budget, Technology, Temperature, Lung, PRP, Integrative Cancer Therapies, Cancer, Growth, OTCQB, Medication, Security (finance), University of Edinburgh, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking manufacturing and development of PRP for human use.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking manufacturing and development of PRP for human use.
  • PRP is the Companys lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V.
  • A proprietary purification process has been developed by Propanc and successful scale up of the bulk drug substances has been completed.
  • Over the last decade, Propanc has undertaken the manufacturing and development of proenzymes as an I.V.

Cannabotech's "Integrative-Colon" products eliminated over 90% of colon cancer cells in a cell model experiment

Retrieved on: 
Tuesday, March 8, 2022
Fortis Healthcare, Patient, Integrative Cancer Therapies, THC, Cannabis, University, Solution, Colorectal cancer, University of Haifa, Company, Cancer, Society for Integrative Oncology, PSK, Neoplasm, Nature, Technology, Physician, Immune system, Cannabinoid, Trametes, Medicinal plants, Medical imaging, Pharmaceutical industry

HERZLIYA, Israel, March 8, 2022 /PRNewswire/ -- Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its "Integrative-Colon" products killed over 90% of colon cancer cells.

Key Points: 
  • HERZLIYA, Israel, March 8, 2022 /PRNewswire/ -- Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its "Integrative-Colon" products killed over 90% of colon cancer cells.
  • The study examined the effect of Cannabotech's Integrative Colon products on various colon cancer subtypes, representing different molecular changes common in these colon cancer subtypes.
  • The study has also demonstrated the different effects of each cannabinoid on distinct subtypes of colon cancer.
  • The Company's products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory.

Cannabotech's "Integrative-Colon" products eliminated over 90% of colon cancer cells in a cell model experiment

Retrieved on: 
Tuesday, March 8, 2022
Fortis Healthcare, Patient, Integrative Cancer Therapies, THC, Cannabis, University, Solution, Colorectal cancer, Drug development, University of Haifa, Company, Cancer, Society for Integrative Oncology, PSK, Neoplasm, Nature, Hadassah Medical Center, Technology, Physician, Immune system, Cannabinoid, Trametes, Medical device, Medicinal plants, Medical imaging, Pharmaceutical industry

HERZLIYA, Israel, March 8, 2022 /PRNewswire/ -- Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its "Integrative-Colon" products killed over 90% of colon cancer cells. The Integrative-Colon products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts.

Key Points: 
  • The Integrative-Colon products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts.
  • The study examined the effect of Cannabotech's Integrative Colon products on various colon cancer subtypes, representing different molecular changes common in these colon cancer subtypes.
  • The study has also demonstrated the different effects of each cannabinoid on distinct subtypes of colon cancer.
  • The Company's products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory.